Dr. Desh Bandhu Gupta, Founder and Chairman of Lupin passes away


Mumbai, India, June 26, 2017: Dr. Desh Bandhu Gupta, Founder and Chairman of Lupin Limited (Lupin), passed away early this morning in Mumbai. He was 79 years old. He will be remembered as a visionary, path-breaker and a nationalist who created a solid legacy of a global pharmaceutical major with a presence in over 100 countries.

Born in Rajgarh, Rajasthan, Dr. Gupta earned a Master of Science Degree (Chemistry) and had a vision to fight life threatening diseases of highest national priority by delivering good quality medicines at an affordable price. It was with this objective that he moved to Mumbai and founded Lupin in 1968.

Since its inception, Lupin has been a pioneer in the Indian pharmaceutical landscape, and it was under the leadership of Dr. Gupta that the company grew from being a domestic Indian pharmaceutical company to a global pharmaceutical major. The company is now the 4th largest generics pharmaceutical player by market capitalization in the world.

A firm believer in the concept of holistic development, Dr. Gupta set-up Lupin Human Welfare and Research Foundation (LHWRF) in 1988 to eradicate poverty by encouraging sustainable development at the grass root level in rural India. His efforts have led to a positive impact on the lives of 2.8 million families in 3,463 villages across India.

Vinita Gupta, CEO and Nilesh Gupta, MD – Lupin, said “We are deeply saddened with the demise of our father early this morning. What DBG put in motion 50 years ago in helping to create, innovate and lead in the pharmaceutical space is an unparalleled legacy. Those who knew and worked with DBG, remember him giving generously and fostering a dynamic environment where people could learn and grow. We will continue to build on his legacy and live by the values he instilled.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 4th and the 6th largest generics pharmaceutical company by market capitalization (March 31st, 2017, Bloomberg) and sales globally (December 31st, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT Feb 2017); the 2nd largest Indian pharmaceutical company by global revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (Quintiles IMS MAT March 2017).

For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
Head – Corporate Communications
Ph: +91-22-66402531 / 09811665000
Email: poojathakran@lupin.com